Key Developments: Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

64.38EUR
25 Jul 2014
Price Change (% chg)

€-1.05 (-1.60%)
Prev Close
€65.43
Open
€65.29
Day's High
€65.35
Day's Low
€64.24
Volume
483,608
Avg. Vol
477,801
52-wk High
€67.78
52-wk Low
€55.20

Search Stocks

Latest Key Developments (Source: Significant Developments)

Merck KGaA completes squeeze-out of AZ Electronic Materials
Wednesday, 2 Jul 2014 08:00pm EDT 

Merck KGaA:Announces that all remaining shares of AZ Electronic Materials (AZ) have been transferred to Merck KGaA on July 2.Holding 99.84 pct of the AZ shares already, Merck KGaA, had exercised its compulsory acquisition right (squeeze-out) on June 27.  Full Article

Merck KGaA and Mersana to develop next-generation antibody-drug conjugates
Tuesday, 24 Jun 2014 01:33am EDT 

Merck KGaA:Mersana and Merck KGaA to develop next-generation antibody-drug conjugates.Says to provide monoclonal antibodies to Mersana.Says to be responsible for clinical development, commercialization of products under exclusive license from Mersana.In addition to upfront payment, Mersana is eligible to receive milestones.  Full Article

Morphosys AG and Merck KGaA's Merck Serono enter strategic immuno-oncology collaboration
Thursday, 12 Jun 2014 01:36am EDT 

Morphosys AG and Merck:Sign agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints.Under terms of agreement, MorphoSys and Merck Serono, biopharmaceutical division of Merck, will join forces to develop therapies that modulate immune system's natural ability to fight tumors.Say MorphoSys will apply its Ylanthia antibody phage library and technology platform to identify antibodies against targets of interest.Say Merck Serono with its portfolio and capabilities in field of immuno-oncology and clinical development will be fully responsible for execution of development from Phase 1 onwards.  Full Article

Merck KGaA announces FDA clearance for Auxogyn's Early Embryo Viability Assessment (Eeva) System
Tuesday, 10 Jun 2014 07:52am EDT 

Merck KGaA:Says that proprietary Early Embryo Viability Assessment (Eeva(R)) System of Merck Serono's strategic partner Auxogyn received clearance from the U.S. Food and Drug Administration (FDA) through its de novo classification process.Says regulatory pathway for select novel, low-to-moderate risk medical devices that are first-of-a-kind.Merck Serono is the exclusive commercial partner of Auxogyn, Inc., for the Eeva System in Europe and Canada.Eeva Test, used adjunctively to traditional morphology, is the first and only prognostic, non-invasive embryo test to receive clearance from the FDA.Says Eeva Test utilizes proprietary software that automatically analyzes embryo development against scientifically derived cell-division timing parameters captured through continual video imaging.This objective information provided to reproductive endocrinologists and embryologists helps to optimize treatment plans for their patients.  Full Article

Merck KGaA to invest in Italian plant-Business Standard
Wednesday, 21 May 2014 04:53am EDT 

Merck KGaA:Will invest 50 million Euros in its Italian production site in Bari-Business Standard.The new production facility in Bari, southern Italy, is to be commissioned in 2017 for the sterile filling and packaging of liquid drugs into syringes, vials and ampoules.  Full Article

Merck KGaA appoints Marcus Kuhnert as Group CFO
Thursday, 8 May 2014 11:47am EDT 

Merck KGaA:Says the Board of Partners of E. Merck KG appointed on May 8 Marcus Kuhnert to the Executive Board of pharmaceuticals and chemicals company Merck as member with unlimited personal liability as of Aug. 1.Says he will assume the role of Group Chief Financial Officer.  Full Article

Merck KGaA announces positive outcome of IIIb study for Kuvan
Wednesday, 23 Apr 2014 08:00pm EDT 

Merck KGaA:Announces Phase IIIb SPARK study has met its primary endpoint.Results of first 26 weeks of study showed that addition of Kuvan (sapropterin dihydrochloride) to phenylalanine-restricted diet in children less than 4 years of age who have phenylketonuria (PKU) and have been shown to be responsive to Kuvan significantly increased tolerance to phenylalanine.This is in comparison with phenylalanine-restricted diet alone.SPARK is Phase IIIb, multicenter, open-label, randomized, controlled study designed to assess efficacy, safety, and population pharmacokinetics of Kuvan in patients younger than 4 years old with PKU and who have been previously shown to be responsive to Kuvan in response test.  Full Article

Oncothyreon announces Merck KGaA initiates phase 3 START2 study with Tecemotide in stage III non-small cell lung cancer
Monday, 7 Apr 2014 06:00am EDT 

Oncothyreon Inc:Says Merck KGaA initiates international Phase 3 START2 study, designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).Merck KGaA, Darmstadt, Germany, is developing tecemotide under a license agreement with Oncothyreon.Merck KGaA, Darmstadt, Germany, obtained the exclusive worldwide rights for development and commercialization of tecemotide from Oncothyreon Inc.  Full Article

Merck KGaA issues FY 2014 outlook in line with analysts' estimates
Wednesday, 5 Mar 2014 07:00pm EST 

Merck KGaA:Expects slight increase in organic sales for FY 2014.Says however, growth is likely to be offset by continued negative foreign exchange effects.Expects as consequence stable sales in FY 2014.Expects to again achieve the 2013 level of EBITDA pre one-time items in FY 2014.FY 2013 sales of 10,700.1 million euros.FY 2014 revenue estimate 11,192 million euros - Thomson Reuters I/B/E/S.FY 2013 EBITDA (pre one-time items) of 3,253.3 million euros.FY 2014 EBITDA estimate 3,305 million euros - Thomson Reuters I/B/E/S.  Full Article

Merck KGaA announces resignation of CFO
Sunday, 26 Jan 2014 03:41pm EST 

Merck KGaA:Announces that Merck Group Chief Financial Officer Matthias Zachert has received the offer to be appointed as Chief Executive Officer of Lanxess AG and he therefore asked for an early release of his duties.Says company will accept this request.  Full Article

BRIEF-Morphosys enters strategic immuno-oncology collaboration with Merck Serono

FRANKFURT, June 12 - Morphosys AG : * Says enters strategic immuno-oncology collaboration * Says Morphosys and Merck Serono enter strategic immuno-oncology collaboration

Search Stocks